Gonorrhea Drug resistance

Sexually transmitted diseases Main Page

Gonorrhea Microchapters

Home

Patient Info

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Gonorrhea from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Antibiotic Resistance

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gonorrhea Drug resistance On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gonorrhea Drug resistance

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gonorrhea Drug resistance

CDC on Gonorrhea Drug resistance

Gonorrhea Drug resistance in the news

Blogs on Gonorrhea Drug resistance

Directions to Hospitals Treating Gonorrhea

Risk calculators and risk factors for Gonorrhea Drug resistance

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  Template:Saram

## Overview[edit | edit source]

The mainstay of therapy for gonococcal infections is antimicrobial therapy. Gonorrhea treatment is complicated by the ability of N. gonorrhoeae to develop resistance to antimicrobials, therefore a combination therapy with Azithromycin and a Cephalosporin is used to improve treatment efficacy and potentially slow the emergence and spread of resistance.

## Drug Resistance[edit | edit source]

* The mainstay of therapy for gonococcal infections is antimicrobial therapy.
* Gonorrhea treatment is complicated by the ability of Neisseria gonorrhoeae to develop resistance to antimicrobials, therefore a combination therapy with Azithromycin and a Cephalosporin is used to improve treatment efficacy and potentially slow the emergence and spread of resistance.
* High-level resistance to these expanded-spectrum cephalosporins is now reported, and it seems developing another effective treatment has become unaffordable.
* Although new combination antibiotic treatments are being evaluated. There are no affordable alternative therapeutic options currently available for the treatment of gonococcal disease. and it seems even newly developed antibiotics will be short solution and may be developed resistance as well.

The drug resistance may be developed by following mechanisms:

* Chromosomal mutations
* Acquisition of R factors (plasmids)

* In 1986, the CDC established the Gonococcal Isolate Surveillance Project (GISP)[1]
* Monitor antimicrobial susceptibility trends in the United States
* Characterize male patients with gonococcal infection
* Phenotypically characterize antimicrobial-resistant isolates of Niesseira gonorrhea

GISP map

### Penicillin[edit | edit source]

Penicillin has not been a first-line treatment option for gonorrhea for a number of decades. However, it has been tested for surveillance purposes.

* In 2012, Almost 13.1% of Niesseria gonorrhea from the GISP survey were resistant to penicillin mainly with two mechanisms:
* Chromosomal penicillin resistance (82.3%)
* Penicillinase production (17.7%)

### Ceftriaxone[edit | edit source]

* In 1987, susceptibility testing for ceftriaxone began and continues to date.
* From 2008 to 2011, ceftriaxone Minimum inhibitory concentrations MICs increased from 0.1% to 0.4%.
* Five isolates with decreased ceftriaxone susceptibility (MIC 0.5 lg/ml) include:
* San Diego, California (1987)
* Cincinnati, Ohio (1992 and 1993)
* Philadelphia, Pennsylvania (1997)
* Oklahoma City, Oklahoma (2012)
* from 2006–2012, the prevalence of elevated Ceftriaxone (MICs) was higher in isolates from Men Who have Sex With Men (MSM) than from Men Who have Sex With women (MSW)

### Cefixime[edit | edit source]

* In 1992, Cefixime susceptibility testing began and was discontinued in 2007
* In 2009, Cefixime susceptibility testing was restarted due to lack of drug supply in the United States
* From 2006 to 2010, ceftixim Minimum inhibitory concentrations (MICs) increased from 0.1 to 1.4
* from 2006–2012, the prevalence of elevated cefixime (MICs) was higher in isolates from Men Who have Sex With Men (MSM) than from Men Who have Sex With women (MSW)

## References[edit | edit source]

1. ↑ Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. JAMA 1990;264:1413–7.

Template:WH Template:WS